CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Titel:
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Auteur:
Chiorean, E.G. Von Hoff, D.D. Reni, M. Arena, F.P. Infante, J.R. Bathini, V.G. Wood, T.E. Mainwaring, P.N. Muldoon, R.T. Clingan, P.R. Kunzmann, V. Ramanathan, R.K. Tabernero, J. Goldstein, D. McGovern, D. Lu, B. Ko, A.